New Publication Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective

The NMD4C is proud to announce that a Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective has been accepted for publication by the Canadian Journal of Neurological Sciences. Notably this consensus statement is authored by NMD4C members Drs. Maryam Oskoui, Hernan Gonorazky, Hugh McMillan, James Dowling, Reshma Amin, Cynthia Gagnon, and Kathryn Selby.

This publication is the first significant research output of the NMD4C, and is a product of the network’s development, dissemination, and implementation of clinical guidelines working group. The working group invited pediatric neuromuscular clinical experts from across the country to provide feedback and direction in adapting existing consensus statements on gene replacement therapy in SMA to the Canadian context.

“It is an exciting time for the neuromuscular field with the advancement of gene therapies. It is our duty as neuromuscular specialists to advocate for safe, equitable, and transparent access to these treatments for all Canadians. We hope that through this consensus we can help inform the application, indication and use of gene replacement therapy in Spinal muscular atrophy.”

– Dr. Hernan Gonorazky.

You can find the publication here.

With three SMA therapies now commercially available in Canada, the working group set out to provide guidance by adapting a set of European consensus statements to a Canadian context and highlighting areas of future need for gene replacement therapy in SMA in Canada. The original publication  from an ad-hoc group of 13 European SMA experts who published a set of consensus statements on the use of gene replacement therapy in SMA using a Delphi consensus process.

The NMD4C will continue to work towards its knowledge translation (KT) goals to improve care standards, train the next generation of neuromuscular researchers and clinicians, and strengthen research infrastructure for better research and more treatments.


Read next...


Clinical and Postdoctoral Research Fellowship Funding Competition from NMD4C, MDC, CSCN Now Open!

The NMD4C, in partnership with Muscular Dystrophy Canada (MDC) is now accepting applications for Post-doctoral Research Fellowships and Clinical Fellowships! These competitions are now open, and will close on November 14, 2022.

National Neuromuscular Lecture Series

National Neuromuscular Lecture Series Provides Training Opportunity for Neuromuscular Clinical Fellows

The NMD4C curriculum working group is pleased to share that the inaugural “National Neuromuscular Lecture Series” kicked off this August 12, 2022. This year-long training curriculum for current Canadian neuromuscular fellows has been developed in consultation with the directors of fellowship programs across Canada. The group decided on 41 topics which constitute a comprehensive neuromuscular knowledge base and identified subject-matter experts from across the country to deliver the weekly lectures.

imPORTND - soft launch image

imPORTND Patient-Oriented Research Training for Neuromuscular Disease Seeks Research Teams for Testing

The NMD4C is excited to introduce our online training platform “imPORTND”, created to help scientists engage with patient partners in research. These modules are designed for all neuromuscular research team members including researchers, staff, and patient partners. imPORTND has been co-developed with a team of expert patient partners, clinicians, and researchers, and offer two modules to help scientists engage with patient partners in research. It is the first patient-oriented research training that focuses specifically on neuromuscular disease.

Myotonic dystrophy foundation logo

2023 Myotonic Dystrophy Foundation Early Career Research Grant

The MDF will issue up to two two-year awards of up to $380,000 at $190,000 per award for early career scholars in the DM field for projects that focus on basic, translational and/or clinical research or care projects in myotonic dystrophy.

welcome to the team - Kevin LaFleur

NMD4C Hire Research Software Developer

The NMD4C are pleased to announce the hiring of research software developer Kevin LaFleur as the most recent addition to the network’s biobanking team! Kevin will develop the technical infrastructure for a centralized Canadian neuromuscular biobanking catalogue.

Global Alliance for DM Awareness Announces Areas of Focus for 2022

International Myotonic Dystrophy Awareness Day 2022 to Take Place September 15th

The NMD4C alongside Muscular Dystrophy Canada (MDC) are proud to be members of a global alliance of over 50 myotonic dystrophy-focused organizations who have once again united to celebrate Myotonic Dystrophy Families Day this past July 23rd, and International Myotonic Dystrophy Awareness Day on September 15th.